Background Rates of atherosclerotic cardiovascular disease (ASCVD) are strikingly high in
India compared to Western countries and are increasing. Moreover, ASCVD events occur at …

The United States and many other countries in the world have benefited from declining rates
of atherosclerotic cardiovascular disease (ASCVD) during the last several decades as a …

Acquisition costs and cost-effectiveness have limited access and recommendations to use
proprotein convertase subtilisin/kexin type 9 (PCSK9)–inhibiting monoclonal antibodies …

Introduction: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are novel
drugs that have been developed since the discovery of the PCSK9 protein in 2003. In …

Background and aims Patients with familial hypercholesterolaemia (FH) may require
proprotein convertase subtilisin/kexin-type 9 (PCSK9) mAb as add-on therapy to achieve …

Objectives: This study sought to define the ability of AMG 145, a monoclonal antibody
directed against proprotein convertase subtilisin kexin type 9 (PCSK9), to enable subjects at …

Background Despite the availability of effective drug therapies that reduce low‐density
lipoprotein (LDL)‐cholesterol (LDL‐C), cardiovascular disease (CVD) remains an important …

Objective Treatment of dyslipidemia lowers cardiovascular (CV) risk. Although statin use is a
cornerstone therapy, many patients are not achieving their risk-specific low-density …

Purpose of Review PCSK9 inhibitors have been shown to be the most effective class of
drugs modifying the levels of LDL-cholesterol as the main risk factor for atherosclerotic …

The role of low-density lipoproteins (LDLs) as a major risk factor for cardiovascular disease
has been demonstrated by several epidemiological studies. The molecular basis for LDLs in …